I-AstraZeneca ithola ukuthuthukiswa kokulawulwa kwezidakamizwa ze-oncology

I-AstraZeneca ithole ukuthuthukiswa okuphindwe kabili kuphothifoliyo yayo ye-oncology ngoLwesibili, ngemuva kokuthi abalawuli baseMelika nabaseYurophu bemukele ukuthunyelwa kwemithi yayo, isinyathelo sokuqala sokuzuza ukugunyazwa kwale mithi.

Umkhiqizi wezidakamizwa wase-Anglo-Swedish, kanye ne-MedImmune, uphiko lwayo lokucwaninga nokuthuthukiswa kwe-biologics emhlabeni wonke, bamemezele ukuthi i-US Food and Drug Administration (FDA) isamukele isicelo selayisense ye-moxetumomab pasudotox, umuthi omusha ongaba khona wokwelapha iziguli ezikhulile ezineseli enoboya. i-leukemia (HCL) abaye bathola okungenani imigqa emibili yokwelashwa yangaphambilini.

I-FDA inikeze lesi sidakamizwa isimo "sokubuyekezwa okubalulekile", esinikezwa imithi okuthi, uma ivunyiwe, inikeze ukuthuthuka okukhulu ekwelapheni, ekuxilongeni, noma ekuvimbeleni izimo ezibucayi. Kulindeleke ukuthi kuthathwe isinqumo ngekota yesithathu yalo nyaka.

Ngokwehlukana, i-European Medicines Agency yamukele ukuhanjiswa okulawulwayo kweLynparza, umuthi i-AstraZeneca manje esewumnikazi wawo ngokubambisana no-50:50 ne-Merck, inkampani yezidakamizwa yaseMelika, ukwelapha umdlavuza webele osabalele kwenye indawo emzimbeni ezigulini ezinohlobo oluthile. ukuguqulwa kofuzo.

Uma ugunyazwa, umuthi uzoba inhibitor yokuqala ye-PARP yokwelapha umdlavuza webele eYurophu. I-PARP iphrotheni etholakala kumangqamuzana omuntu esiza lawo maseli ukuthi akwazi ukuzilungisa uma onakele. Ngokumisa le nqubo yokulungisa kumaseli omdlavuza, ama-PARP inhibitors asiza iseli ukuthi life.

I-Lynparza ngoJanuwari ibe inhibitor yokuqala ye-PARP egunyazwe noma yikuphi emhlabeni ngomdlavuza webele, lapho iwina imvume kubalawuli baseMelika.

Ocwaningweni lwakamuva, u-Lynparza wandise kakhulu ukusinda okungaqhubeki uma kuqhathaniswa nokwelashwa ngamakhemikhali futhi wehlisa ingozi yokuqhubeka kwesifo noma ukufa ngamaphesenti angama-42.

Ngo-2017 ingxenye yesihlanu yokuthengiswa komkhiqizo wakwa-Astra yayivela ku-oncology futhi inkampani ilindele ukuthi lesi silinganiso sikhuphuke. Amasheya eqenjini avale ngamaphesenti angu-0.6 ngo-£49.26.

Kwenye intuthuko ehlukile, iCompugen, okuyinkampani yase-Israel ekhiqiza imithi, ithe yenze isivumelwano selayisense esikhethekile ne-MedImmune esizokwenza ukuthi kuthuthukiswe imikhiqizo ye-antibody yokwelapha umdlavuza.

I-MedImmune inelungelo lokudala imikhiqizo eminingi ngaphansi kwelayisensi "futhi izoba nesibopho kuphela kulo lonke ucwaningo, ukuthuthukiswa kanye nemisebenzi yezohwebo ngaphansi kwesivumelwano", kusho uCompugen.

Inkampani yakwa-Israeli izothola inkokhelo yangaphambili engu-$10m futhi ifaneleka ukuthola kufika ku-$200m ekuthuthukisweni, ezimisweni zokulawula nezohwebo zomkhiqizo wokuqala, kanye nezinzuzo ekuthengisweni komkhiqizo esikhathini esizayo.

U-Anat Cohen-Dayag, isikhulu esiphezulu seCompugen, uthe isivumelwano “sivumela ukuthi senze imali ngentuthuko ethile yesayensi ezinhlelweni zethu, kuyilapho siqhubeka nokuqhubekisela phambili izinhlelo zethu eziholela ekuhlolweni kwemitholampilo”.